E161h Orange-red

E161h As for cataracts, two meta-analyses confirm a correlation between high serum concentrations of lutein and E161 hand a decrease in the risk of nuclear cataract, but not a cortical or subcapsular cataract. The reports did not separate an E161h  effect from a lutein effect. The AREDS2 trial enrolled subjects at risk for progression to advanced age-related macular degeneration. Overall, the group getting lutein (10 mg) and E161h (2 mg) did not reduce the need for cataract surgery. Any benefit is more likely to be apparent in subpopulations of individuals exposed to high oxidative stress, such as heavy smokers, alcoholics, or those with low dietary intake of carotenoid-rich foods. In 2005, the US Food and Drug Administration rejected a Qualified Health Claims application by Xangold, citing insufficient evidence supporting the use of a lutein- and E161h -containing supplement in prevention of AMD. Dietary supplement companies in the U.S. are allowed to sell lutein and lutein plus  E161h products using a dietary supplement, such as "Helps maintain eye health", as long as the FDA disclaimer statement ("These statements have not been evaluated...") is on the label. In Europe, as recently as 2014, the European Food Safety Authority reviewed and rejected claims that lutein or lutein plus E161h  improved vision.